Barclays analyst Carter Gould lowered the firm’s price target on Bristol-Myers to $62 from $64 and keeps an Equal Weight rating on the shares post the Q2 results. The analyst says the company is “clearing the decks” ahead of the CEO transition. The firm sees a “challenging catalyst path” for Bristol-Myers, offset by its new new $4B buyback program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- 2seventy Bio downgraded to Equal Weight from Overweight at Morgan Stanley
- Cutera upgraded to Neutral at Piper after CEO appointment
- Bristol-Myers Squibb (NYSE:BMY) Tanks on Q2 Miss; Guidance Disappoints
- Bristol-Myers cuts FY23 adjusted EPS view to $7.35-$7.65 from $7.95-$8.25
- Bristol-Myers announces $4B accelerated share repurchase agreement